Beyond Scared Straight Seth Now, Rottmnt Mikey Fanfiction, Articles G

340), 1. POSTER: Real-world assessment of patients with ovarian cancer who received niraparib as second-line maintenance therapy in the United States: did first-line maintenance approval change the patient profile for second-line maintenance therapy? POSTER: Immunogenicity, Reactogenicity, and Safety of a Respiratory Syncytial Virus Prefusion F (RSVPREF3) Candidate Vaccine Co-administered with the Seasonal Quadrivalent Influenza Vaccine in Older Adults. 2. 6. Poster No. Please help us protect Glassdoor by verifying that you're a Effects of Daprodustat on Hemoglobin and Quality of Life in Non-Dialysis CKD Patients: Expanded Results of the ASCEND-NHQ Trial? 2017;130(suppl 1): 1377. Impact of the COVID-19 Pandemic on Health Care Resource Utilization (HCRU) and Costs in Chronic Obstructive Pulmonary Disease (COPD) in the United States: A Population-Based Study. Describing asthma control and adherence in patients with extended Salford Lung Study (Ex-SLS) prescribed inhaled corticosteroids/long-acting beta agonists (ICS/LABAs). 3888792. Stability Calculator, Click here if you are not a US Healthcare Professional, Patient, or Caregiver. 7. Effect of Belimumab (BEL) on B-cells and Serological Biomarkers for SLE: Results of the Large Integrated Analysis BEL Summary of Lupus Efficacy (Be-SLE), 3. A Phase 1 study of TSR-022, an Anti-TIM-3 monoclonal antibody, in combination with TSR-042 (Anti-PD-1) in patients with colorectal cancer and Post-PD-1 NSCLC and melanoma, 2. Associations between haemoglobin values and rate of changes with MACE in the ASCEND-ND randomised clinical trial. POSTER: Utility of circulating tumor DNA in lung cancer clinical research and practice: systematic review and meta-analysis, 3. ORAL PRESENTATION: Kohli A, et al. Triple checkpoint blockade targeting PD-1, TIM-3, and LAG-3 improves T cell reinvigoration and antitumor efficacy over single and double combinations, 1. Seasonal Efficacy of Mepolizumab in Patients With Severe Eosinophilic Asthma ? 2. Comparison of Peak Inspiratory Flow Rate Between Clinical Trial and Real-World Populations. Hellmich B, Neukirch K, Lukas M, et al. 6. Si continas viendo este mensaje, [Poster No. Youll have opportunities to work on challenging projects and assignments that will help you grow, thrive, and reach your full potential. Phase 2 study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-? Get email updates for new Gsk Medical Affairs jobs in United States. Reasons why patients with severe asthma discontinue biologic treatment, Impact of mepolizumab in patients with life-threatening asthma, CAPTAIN Study: Effect of baseline lung function on response to triple therapy in patients with asthma inadequately controlled on inhaled corticosteroid/long-acting ?2-agonist therapy, Views of US pulmonologists on the prevalence of uncontrolled asthma, treatment decisions and the role of treatable traits: results from the CHEST Pulse Surveys, CAPTAIN Study: Association of moderate and severe asthma exacerbations with lung function and patient-reported outcomes in a large randomized phase III clinical trial, Prevalence of asthma control and the associated disease burden in US patients with asthma treated with a fixed-dose combination of inhaled corticosteroid and long-acting ?2-agonist, Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol compared with tiotropium monotherapy in chronic obstructive pulmonary disease: a post hoc analysis by airflow limitation, Real-world adherence to single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in a commercially insured US population, Risk of death and chronic obstructive pulmonary disease (COPD) hospitalization with fluticasone furoate-containing therapy: Post hoc subgroup analysis from the SUMMIT trial in patients with COPD and a history of exacerbation, Demographic and clinical characteristics of patients experiencing on-treatment exacerbations, on-treatment death or premature study treatment withdrawal: The IMPACT Trial, Time-dependent risk of cardiovascular events following an exacerbation in patients with COPD: post hoc analysis from the IMPACT trial, Benefit?risk profiles of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus UMEC/VI in patients with chronic obstructive pulmonary disease: a Markov model, Genetic variants do not predict acute COPD exacerbations or treatment response to fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) and its components, Cross-sectional survey to assess chronic obstructive pulmonary disease (COPD) medication use by United States (US) physicians, Cross-sectional survey to assess the burden of nocturnal symptoms in patients with chronic obstructive pulmonary disease (COPD), Medication adherence and COPD-related costs among patients with COPD treated with umeclidinium/vilanterol (UMEC/VI) versus tiotropium (TIO), Umeclidinium/vilanterol (UMEC/VI) compared with tiotropium (TIO) for time-to-first inpatient admission among patients with chronic obstructive pulmonary disease in a managed care population, Impact of umeclidinium/vilanterol (UMEC/VI) versus tiotropium (TIO), fluticasone propionate/salmeterol (FP/SAL), and budesonide/formoterol (B/F) on time-to-first severe exacerbation among patients with chronic obstructive pulmonary disease with high comorbidities and high costs, Assessment of patient interaction with a dry powder inhaler electronic medication monitor and integrated system within the Chronic Obstructive Pulmonary Disease Foundation Patient Powered Research Network, Chronic obstructive pulmonary disease is associated with an increased risk of herpes zoster: a retrospective analysis of a United States claims database from 2013-2018, Real-World Impact of Mepolizumab on the Oral Corticosteroid Freedom Component of Clinical Remission in Severe Eosinophilic Asthma: International, Prospective REALITI-A Study. Genes Dev. Part 1 Results of a Dose Finding Study of Belantamab mafodotin (GSK2857916) in Combination with Pomalidomide (POM) and Dexamethasone (DEX) for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM), 1. Preliminary Safety, Efficacy, and PK/PD Characterization from GARNET, a Phase 1 Clinical Trial of the Anti-PD-1 Monoclonal Antibody, TSR-052, in Patients with Recurrent or Advanced MSI-H Endometrial Cancer, 4. Silver J, Bogart M, Molfino N, et al. POSTER: Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease following first-line chemotherapy: PRIMA/ENGOT-OV26/GOG-3012 ad-hoc subgroup analysis, 7. Exacerbation Reduction in Patients Based Upon Baseline Eosinophil Counts and FEV1 Reversibility. P813; Abstract A4302]. Patient Experience of Physician-Patient Communication and Delayed or Misdiagnosis in Patients With Eosinophil-Driven Diseases. Apprentice programmes Kickstart a brilliant career with hands-on experience from day one. Continuity of Care Assessment Within a Vertically Integrated Care Management Organization Before and After COPD-related Exacerbations. Richards A, et al. Treatment Patterns and Disease Burden of Triple Therapy in Asthma. 6. [Poster No. PLAIN LANGUAGE SUMMARY [HCP USE ONLY]: The DREAMM-2 Study: Effects of Belantamab Mafodotin in Patients With Multiple Myeloma Who Had Already Been Treated Unsuccessfully With Several Anti-Myeloma Treatments, 13. Improvements in COPD Symptoms With Umeclidinium/Vilanterol Analyzed by Baseline CAT Score: A Post Hoc Analysis of the EMAX Trial. This site is intended for US healthcare professionals only. 2. 1. MyOldMeds.com/blogrV. Vogelmeier CF, Kerwin EM, Naya IP, et al. Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom. 3888792. If not, try adjusting your search terms or contact GSK Medical Information at 1-877-GSK-MI4U (1-877-475-6448) You can unsubscribe from these emails at any time. 8. P1458. Changes in Oral Corticosteroid (OCS) Use Following Initiation of Mepolizumab Therapy in Patients with Asthma. 5. POSTER: Discovery and characterization of the CD96 antibody GSK6097608, a high-affinity, antagonistic anti-CD96 antibody for cancer immunotherapy, 1. Effect of Serostatus on the Efficacy of Sotrovimab in Preventing COVID-19 Progression, 2. POSTER: Unmet needs in metastatic synovial sarcoma across EU-5 countries, 6. Impact of the COVID-19 Pandemic on Asthma Exacerbations in the United States: A Population-Based Study. Improvements in COPD Symptoms With Umeclidinium/Vilanterol Analyzed by Baseline CAT Score: A Post Hoc Analysis of the EMAX Trial. Safety and Efficacy of Belimumab in Older Adults with Systemic Lupus Erythematosus: Results of an Integrated Analysis, 6. Comparative Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review and Network Meta-Analysis. Coyne DW, et al. P805; Abstract A7742]. Brentford TW8. ORAL PRESENTATION: Final overall survival and long-term safety in the ENGOT-OV16/NOVA phase III trial of niraparib in patients with recurrent ovarian cancer, 2. Trends Cancer. 1301; Abstract A1312]. Si continas recibiendo este mensaje, infrmanos del problema Associations between haemoglobin values and rate of changes with MACE in the ASCEND-ND randomised clinical trial. Blood. Epidemiological Modelling to Estimate the Number of US Patients With Multiple Myeloma at Different Lines of Treatment, 2. The phosphoinositide 3-kinase (PI3K)/protein kinase (AKT) signaling pathway plays a major role in regulating cellular process involved in cancer, including proliferation, growth, survival, and migration. 5. Eur J Immunol. 2. GSK3196165 An investigational anti-GM-CSF monoclonal antibody, improves patient reported outcomes in a phase IIB study of patients with rheumatoid arthritis, 2. 5. Wenn 2015;16(9):21138-21152. [Poster No. GSK ViiV (GSK) Global Medical Affairs Director Durham, NC 30d+ $121K-$193K Per Year (Glassdoor est.) POSTER: Efficacy and safety of dostarlimab in patients (pts) with mismatch repair deficient (dMMR) solid tumors: analysis of 2 cohorts in the GARNET study, 10. P786; Abstract A5624]. Expression of myeloma cell BCMA and soluble BCMA in relapsed and refractory multiple myeloma subjects treated with GSK2857916 in BMA117159, 4. POSTER: Immuno-PET monitoring of CD8 + T cell infiltration post anti-ICOS agonist antibody treatment alone and in combination with PD-1 blocking antibody using a 89Zr anti-CD8+ mouse minibody in EMT 6 syngeneic tumor mouse, 4. Vaccine Temperature [Poster No. POSTER: Kaye KS, Gupta V, Mulgirigama A, et al. 801; Abstract A7738]. Poster No. PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes. Cookies will only be set if you choose to accept them. ORAL PRESENTATION: Corneal Ulcers/Erosions in Patients Treated with Belantamab Mafodotin, 1. POSTER: Progression-free survival (PFS) and overall survival (OS) in patients (pts) with mismatch repair deficient (dMMR) solid tumors treated with dostarlimab in the GARNET study, 7. Symptom Burden in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy. ORAL PRESENTATION: Evolution of the Ovarian Cancer Treatment Paradigm, Including Maintenance Treatment, In the US and Europe: A Real-World Chart Review Analysis (2017?2020), 1. 3. GSK Solid Tumor Oncology Account Manager; Long Island East, NY Long Island-Queens 30d+ $160K-$216K Per Year (Employer est.) P1481. GSK is investigating the activity of two compounds that target protein arginine methyltransferases (PRMTs).